Chinese Pre-Profit Cancer Drug Developer Tot Biopharm Files For HK IPO

Login to View

Tot Biopharm, a private equity-backed Chinese biopharmaceutical company, has filed for an initial public offering (IPO) in Hong Kong on Monday under the rules that allow pre-profit companies to float shares on the stock exchange.

China Money Network

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech


Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!


Already have an account or paid subscription? Log in


RELATED NEWS



LEAVE A REPLY